Search
Search Results
-
Rituximab potentially improves clinical outcomes of CAR-T therapy for r/r B-ALL via sensitizing leukemia cells to CAR-T-mediated cytotoxicity and reducing CAR-T exhaustion
PurposeDespite chimeric antigen receptor (CAR) T-cell therapy has achieved great advances in recent year, approximately 50% of relapsed/refractory B...
-
CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude
BackgroundChimeric antigen receptor (CAR) T cell therapy is associated with high risk of adverse events. Glucocorticoids (GCs) are cornerstone in the...
-
CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models
BackgroundRhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in childhood, whose prognosis is still poor especially for metastatic,...
-
Cellular Therapies for Cancer: Chimeric Antigen Receptor T Cells (CAR-T)
Chimeric antigen receptor T cell (CAR-T), a novel modality of adoptive cellular therapy, is characterized by the expression of chimeric antigen...
-
The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments
BackgroundChimeric antigen receptor-T (CAR-T) cells therapy is one of the novel immunotherapeutic approaches with significant clinical success....
-
Myeloid leukemia-derived galectin-1 downregulates CAR expression to hinder cytotoxicity of CAR T cells
BackgroundChimeric antigen receptor (CAR) T cells have shown significant activity in B-lineage malignancies. However, their efficacy in myeloid...
-
Control of the antitumour activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumour cells
On-target off-tumour toxicity limits the anticancer applicability of chimaeric antigen receptor (CAR) T cells. Here we show that the tumour-targeting...
-
Harnessing CD3 diversity to optimize CAR T cells
Current US Food and Drug Administration-approved chimeric antigen receptor (CAR) T cells harbor the T cell receptor (TCR)-derived ζ chain as an...
-
CRISPR/Cas-based CAR-T cells: production and application
Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized the treatment approach for cancer, autoimmune disease, and heart disease. The...
-
A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells
The manufacturing of autologous chimaeric antigen receptor (CAR) T cells largely relies either on fed-batch and manual processes that often lack...
-
How to Test Human CAR T Cells in Solid Tumors, the Next Frontier of CAR T Cell Therapy
Chimeric antigen receptor (CAR) T cell therapy has proven to be a successful treatment option for leukemias and lymphomas. These encouraging outcomes...
-
Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR
The effectiveness of chimaeric antigen receptor (CAR) T cell therapies for solid tumours is hindered by difficulties in the selection of an effective...
-
Generation of Anti-HIV CAR-T Cells for Preclinical Research
The inability of people living with HIV (PLWH) to eradicate human immunodeficiency virus (HIV) infection is due in part to the inadequate...
-
SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors
Despite the tremendous progress of chimeric antigen receptor T (CAR-T) cell therapy in hematological malignancies, their application in solid tumors...
-
Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer
BackgroundOvarian cancer (OC) is characterized by its rapid growth and spread which, accompanied by a low 5-year survival rate, necessitates the...
-
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
BackgroundRecent progress in cancer immunotherapy encourages the expansion of chimeric antigen receptor (CAR) T cell therapy in solid tumors...
-
Genome Editing in CAR-T Cells Using CRISPR/Cas9 Technology
CAR-T cell therapy is revolutionizing the treatment of hematologic malignancies. However, there are still many challenges ahead before CAR-T cells...
-
Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells
The efficacy of adoptive T-cell therapies based on chimaeric antigen receptors (CARs) is limited by the poor proliferation and persistence of the...
-
Deciphering the importance of culture pH on CD22 CAR T-cells characteristics
BackgroundChimeric antigen receptor (CAR) T-cells have demonstrated significant efficacy in targeting hematological malignancies, and their use...
-
IL-24 improves efficacy of CAR-T cell therapy by targeting stemness of tumor cells
BackgroundCancer stem cells (CSCs) induce therapeutic resistance and may be an important barrier to cancer immunotherapy. Chimeric antigen receptor T...
